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mi).The present study discusses the efﬁcacy of Aloe emodin-8-O-glycoside (AEG), a plant derived anthro-
quinone, on alleviating insulin resistance and augmenting glycogen synthesis in L6 myotubes and
3T3L1 adipocytes. Dose-dependent increase in glucose uptake activity (GUA) was observed in both
cell lines. Immunoblot analysis revealed an insulin-like glucose transporting mechanism of AEG
by activating key markers involved in the insulin signaling cascade such as insulin receptor beta
IRb, insulin receptor substrate1, 85 phosphatidyl inositol 30 kinase (PI3K) and PKB. Glucose trans-
porter 4 translocation was conﬁrmed by determining the uptake of glucose in the presence of insu-
lin receptor tyrosine kinase and PI3K inhibitors. AEG was found to enhance glycogen synthesis
through the inhibition of glycogen synthase kinase 3b. In conclusion, AEG enhances glucose trans-
port by modulating the proximal and distal markers involved in glucose uptake and its transforma-
tion into glycogen.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Insulin resistance is a key pathophysiological feature of type 2
diabetes. Impaired insulin secretion and free radical formation
are the initial events triggering the development of insulin resis-
tance and its causal relations with dysregulation of glucose and
fatty acids metabolism. Although numerous oral hypoglycemic
drugs exist alongside insulin, there is no promising therapy for
NIDDM [1]. Some of the drugs such as sulphonylureas, and a fewchemical Societies. Published by E
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ibs1@yahoo.com (B.S. Laksh-biguanides are valuable drugs for the treatment of hyperglycemia
in NIDDM. However, these therapies are limited by their poor
pharmacokinetic properties, secondary failure rates and accompa-
nying side effects [2]. Hence in type 2 diabetic patients, the de-
creased ability of insulin to stimulate glucose disposal into
muscle or adipose tissues results in insulin resistance [3]. Although
the molecular basis of type 2 diabetes is poorly understood, it is
well established that insulin signaling, including the activation of
insulin receptor activity, is impaired in most of the patients with
NIDDM.
In the present study, a pure compound was isolated from Cassia
ﬁstula which exhibited enhanced glucose uptake. The uptake of
glucose and its mechanism of action were deciphered using an
in vitro model. Based upon the glucose uptake activity the active
extract was prioritized for puriﬁcation. Bioassay aided column
puriﬁcation resulted in the isolation of a bioactive molecule which
upon further structural characterization was elucidated as Aloe
emodin glycosides (AEG) (Fig 1). Aloe emodin has been originally
isolated from Aloe vera leaf [4] and from the root and rhizome of
Rheum palmatum L. [5,6] and has also been reported for its anti-
proliferative effect on various cancer cells like merkel carcinoma
cells [7,8] liver cancer cell lines (Hep G2 and Hep 3B) and human
promyelocytic leukaemic cells (HL-60) [9]. It has been reportedlsevier B.V. All rights reserved.
Fig. 1. Structure of the bio active pure compound chemically characterized as 8-(4,
5-dihydroxy-6 hydroxyl methyl-tetrahydro-pyran-3yloxy)-1-hydroxy-3-hydroxy-
methyl-anthraquinone, with molecular formula C21H22O10, molecular mass 434 and
identiﬁed as Aloe emodin glycosides.
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hypotensive agent that leads to 79% fall in arterial blood pressure
at a dose of 3 mg/kg [11]. The molecular mechanism of AEG was
unknown and this is the ﬁrst report for AEG from Cassia ﬁstula that
stimulates glucose uptake and glycogen storage via insulin signal
transduction pathway.
2. Materials and methods
2.1. Chemicals and reagents
The chemicals were obtained from Sigma–Aldrich, St. Louis. All
cell culture solutions and supplements were purchased from Life
Technologies Inc. (Gaithersburg, MD, USA). Dulbecco’s Modiﬁed
Eagle Medium (DMEM) was obtained from GIBCO, BRL (Carlsbad,
CA, USA). 2-DeoxyD-[1-3H] glucose and hybond C membrane were
obtained from Amersham Pharmacia Biotech, (Buckinghamshire,
UK). Insulin, Genistein and Protein A Sepharose beads were ob-
tained from Sigma–Aldrich (Andover, U.K.). Wortmannin was ob-
tained from Calbiochem (Darmstadt, Germany). Rosiglitazone
(RSG) was a kind gift from Dr. Reddy’s Laboratories, Hyderabad.
All the antibodies were procured from BD Pharmingen (San Diego,
CA, USA) and Calbiochem. CytoTox 96 cytotoxicity assay kit was
procured from Promega, USA.
2.2. Cell culture of L6 myotubes and 3T3L1 adipocytes
L6, a monolayer myoblast culture (obtained from ATCC-CRL-
1458) and 3T3L1 preadipocytes (obtained from ATCC-CL-173) were
cultured in DMEM with 10% foetal bovine serum (FBS) and supple-
mented with penicillin (120 units/ml), streptomycin (75 lg/ml),
gentamycin (160 lg/ml) and amphotericin B (3 lg/ml) in a 5%
CO2 environment. For differentiation, the L6 cells were transferred
to DMEM with 2% FBS for 4 days, post-conﬂuence. The extent of
differentiation was established by observing the multinucleate of
cells. 3T3L1 preadipocytes grown in 24 well plates until 2 days
post-conﬂuence and the cells were induced by the differentiation
medium (combination of 0.5 mM/l of IBMX, 0.25 lM/l of DEX
and 1 mg/l of insulin in DMEM medium with 10% FBS) to differen-
tiate into adipocytes. Three days after induction, the differentiation
medium was replaced with medium containing 1 mg/ml insulin
alone. The medium was subsequently replaced again with fresh
culture medium (DMEM with 10% FBS) after 2 days the extent of
differentiation was measured by monitoring the formation of mul-
tinucleation in cells.
2.3. Measurement of 2-deoxy-D-[1-3H] glucose
L6 myoblasts and 3T3L1 preadipocytes grown in 24 well plate
were subjected to glucose uptake as reported [12]. In brief, differ-entiated cells were serum starved for 5 h and were incubated with
AEG for 24 h and then cells were either stimulated with 10 nM
insulin or left untreated for 20 min. After experimental incubation,
cells were rinsed once with HEPES buffered Krebs Ringer phos-
phate solution (118 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.2 mM
MgSO4, 1.2 mM KH2PO4 and 30 mM HEPES and pH 7.4) and were
subsequently incubated for 15 min in HEPES buffered solution con-
taining 0.5 lCi/ml 2-deoxy-D-[1-3H] glucose. The uptake was ter-
minated by aspiration of media. Cells were washed thrice with
ice cold HEPES buffer solution and lysed in 0.1% sodium dodecyl
sulphate (SDS). The lysates were transferred to the plate with glass
ﬁber paper and allowed to air dry. This plate was used to measure
the cell-associated radioactivity by liquid scintillation counter. All
the assays were performed in duplicates and repeated thrice for
concordance. Results have been expressed as % glucose uptake
with respective control. The % of glucose uptake was measured
by applying counts per minute (CPM) values to the formula (Cell-
s + AEG treated with insulin  Control (only cells) treated with
insulin/Control (only cells) treated with insulin)  100 and (Cell-
s + AEG without insulin  Control (only cells) without insulin/Con-
trol (only cells) without insulin)  100.
2.4. Bio activity guided structure elucidation
Based on the 2-deoxy-D-[1-3H] glucose uptake studies the active
methanolic extract was further puriﬁed and purity was established
by HPLC. The structure of the active compound was determined by
1H, 13C nuclear magnetic resonance spectroscopy (NMR). The mass
spectra conﬁrmed the elemental composition of the compound.
Amorphous yellow coloured powder (MeOH), IR (KBr): 3367, 2886,
1667, 1613, 1578, 1524, 1442, 1085. 1H NMR (500 MHz, dimethyl
sulphoxide (DMSO)d6) d: 6.78 (1H, dd, H-2), 7.19 (1H, dd, H-4),
7.28 (1H, s, H-5), 7.46 (1H, m, H-6), 7.02 (1H, dd, H-7), 4.85 (2H, s,
CH2–3), 5.0 (1H, s, OH-1), 2.6 (1H, s, CH2OH-3), 3.88 (1H, s, glu-CH),
3.96 (2H, s, glu-CH2), 3.76 (1H, s, glu-CH), 3.04 (1H, s, glu-CH), 3.91
(1H, s, glu-CH), 3.62 (2H, s, glu-CH2), 2.0 (4H, s, 4 glu-OH). 13C
NMR (100 MHz, DMSOd6) d: 160.8 (C-1), 100.1 (C-2), 148.7 (C-3),
68.8 (C-CH2OH), 115.4 (C-4), 123.1 (C-2’), 145.2 (C-3’), 115.6 (C-5),
132.5 (C-6), 102.4 (C-7), 162.1 (C-8), 130.0 (C-6’), 110.2 (C-7’),
190.1 (C-9, carbonyl), 190.1 (C-10, carbonyl), 76.2 (glu-C-1), 67.5
(glu-C-2), 74.1 (glu-C-3), 69.2 (glu-C-4), 75.9 (glu-C-5), 65.2 (glu-
C-6).Massdatam/z: 434 (M+).Basedon thecharacterization, the iso-
lated compound was found to be AEG (8-(4, 5-dihydroxy-6–hydro-
xylmethyl- tetrahydro-pyran-3yloxy)-1-hydroxy-3-hydroxymethyl-
anthraquinone) and molecular formula was found to be C21H22O10
with a molecular mass of 434.
2.5. Assessment of cytotoxicity by lactate dehydrogenase (LDH) release
assay
Lactate dehydrogenase (LDH) release assay was performed [13]
using a cytotox 96 assay kit (Promega) by quantitatively measuring
LDH, a stable cytosolic enzyme released during cell lysis. The assay
was done with 0.2  106 cells/0.2 ml/well, seeded in 96 well cell
culture plates. Triton X-100 (0.05%) was used to induce maximal
lysis. The plate was read at 492 nm in a scanning multiwell
spectrophotometer. LDH was measured in supernatants by using
the formula % LDH release = [(ODsample  ODcontrol)/(ODTritonX 
ODcontrol)]  100.
2.6. 3T3L1 adipocyte differentiation inhibition and Adipo red staining
3T3L1 preadipocytes were induced by the combination of IBMX,
DEX and insulin to differentiate into adipocytes as previous de-
scribed (day 0). 72 h after induction, the differentiation medium
was replaced with 10% FBS–DMEM containing 1 mg/l insulin for
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medium for 48 h (day 7). The degree of the differentiation of the
cells was investigated by adding AEG at logarithmic doses ranging
from 1 pg/ml to 1 lg/ml from day 0, a period of time which cov-
ered the entire induction and post induction stages. Alternatively,
preadipocytes were maintained with fresh FBS–DMEM every other
day for the whole spectrum of induction period [14]. AdipoRed li-
pid staining assay (Lonza Walkersville Inc.) was performed at the
end of the induction period to monitor the degree of differentiation
as described above. Photomicroscopic evaluation was also carried
out for the comparison of triglyceride accumulation.
2.7. PTP1B inhibition assay
The enzymatic assay was carried out in sodium acetate buffer,
in a 96 well format. The initial rate of protein tyrosine phosphatase
1B (PTP1B)-catalyzed hydrolysis of p-nitrophenyl phosphate
(pNPP) was measured by following the absorbance change at
405 nm. Puriﬁed recombinant human PTP1B from Biomol was used
for the study. Effect of AEG on PTP1B enzyme inhibition was deter-
mined at ﬁxed enzyme and substrate concentration.
2.8. Inhibitor studies
Glucose uptake analysis in presence of inhibitors such as geni-
stein, wortmannin was performed as explained [15,16]. Brieﬂy,
L6 myotubes were serum starved for 5 h and pre-treated with
the inhibitors wortmannin (100 nM) and genistein (50 lM) respec-
tively for 30 min. AEG was incubated for 24 h and their effect on
glucose uptake was measured as mentioned earlier.
2.9. Immunoprecipitation and immunoblotting
L6 myotubes were treated with optimum concentrations of AEG
after serum deprivation. Total cell lysates were prepared as re-
ported previously [17]. Anti insulin receptor substrate1 (IRS1) anti-
body was added to the eppendorf tube containing the cold lysates
and incubate at 4 C for 1 h. Protein A Sepharose (50 ll) beads was
activated by washing with cold lysis buffer (500 ll) and centri-
fuged at 10 000g for 30 s twice. Finally, 50 ll of washed Protein
A Sepharose slurry was added to total protein (125 lg) isolated
from AEG treated L6 myotubes and immunoprecipitated for 1 h
at 4 C on a rocking platform. The eppendorf was spun at
10 000g for 1 min at 4 C for washing and this step was per-
formed 3–5 times with 500 ll of lysis buffer. After the last wash,
50 ll of 1 laemmli sample buffer was added to bead pellet, vor-
texed and heated to 90–100 C for 10 min. This was spun at
10 000g for 5 min and the resultant supernatant was loaded onto
10% SDS–polyacrylamide gel, electrophoretically transferred onto a
nitrocellulose membrane. Then, the membrane was blocked over-
night in blocking agent (5% skimmed milk) at 4 C and incubated
with desired primary antibody for 2 h. After washing, membrane
was incubated with alkaline phosphatase conjugated secondary
antibody in 5% BSA in PBS for 1 h at room temperature. Then the
blot was washed with PBS thrice, each 5 min and the blot was
developed with the nitroblue tetrazolium/5-bromo-4-chloro-3-
indolylphosphate NBT/BCIP chromogenic agent and photographed.
The immunoblots were probed with the respective primary anti-
body with phosphorylated and non-phosphorylated form of insulin
receptor beta (IRb), IRS1, phosphatidyl inositol 30 kinase (PI3K),
PKB, glucose transporter 4 (GLUT4), glycogen synthase kinase 3b
(GSK3b) and peroxisome proliferator activator receptor gamma
(PPARc), followed by speciﬁc secondary antibody and visualized
using a chromogenic substrate. The density of the protein bands
were quantitated by densitometry scanning (Chemi Imager 4400,
Alpha Innotech Corporation).2.10. Sub-cellular membrane fractionation
Sub-cellular fractionation of plasma membranes was carried
out as described [18] with some modiﬁcations. Brieﬂy, L6 myotu-
bes after treatment with AEG was washed and re-suspended in
buffer I (250 mM/l sucrose, 5 mM NaN3, 20 mM HEPES, 200 lM/l
PMSF, 1 lM/l pepstatin, 1 lM/l aprotinin and 2 mM/l EGTA, pH
7.4). Cell lysate was homogenized using 20 strokes of a Dounce
homogenizer (0.5 cycles, 10 pulses; 2 min each and lag time of
1 min for each pulse). Lysates were centrifuged at 750g for
5 min at 4 C to remove cell debris. The plasma membrane (PM)
fraction was obtained by centrifugation of the resulting superna-
tant at 30 000g for 40 min at 4 C. The resultant pellet was re-sus-
pended in buffer I and this constitutes the PM fraction. Supernatant
was removed and centrifuged at 100 000g for 75 min at 4 C to
generate the cytosol fractions. The light microsome (LM) pellet
was re-suspended in buffer I and assayed for soluble protein con-
tent by Bradford’s assay. The membrane fractions were subjected
to electrophoresis on 10% SDS–PAGE, transferred to nitrocellulose
membranes, and immunoblotted with anti-GLUT4 antibody.
2.11. Glycogen synthesis
Glycogen level was measured as described early [19]. In brief,
completely differentiated L6 myotubes were serum starved for
5 h and treated with different concentrations of AEG for 24 h. After
the speciﬁed time point, cells were either stimulated with 10 nM
insulin or left untreated for 20 min and then pulsed with 1 lCi/
ml [14C] glucose in genistein (GS) buffer (2.5 mM glucose, 0.1%
BSA, 25 mM HEPES, pH 7.4) and incubated for 30 min at 37 C.
The cells were then lysed in 30% KOH and 20 mg/ml of carrier gly-
cogen was added and heated for 30 min at 70 C. Glycogen synthe-
sized was then precipitated using ice cold ethanol at 20 C for 24 h
and centrifuged at 2000g for 10 min. The glycogen pellet was
dried and dissolved in 200 ll of water and counted in liquid scin-
tillation counter. The % of glucose incorporation into glycogen
was measured by applying CPM values to the formula (Cells + AEG
treated with insulin  Control (only cells) treated with insulin/
Control (only cells) treated with insulin)  100 and (Cells + AEG
without insulin  Control (only cells) without insulin/Control (only
cells) without insulin)  100.
2.12. Statistical analysis
Statistical analysis was performed using GraphPad Prism, 4.03
(San Diego). One way analysis of variance (ANOVA) followed by
Dunnett’s post hoc used for other parameters. Data were expressed
in means ± S.E.M. The criterion for statistical signiﬁcance was
P < 0.05.
3. Results
3.1. AEG stimulates glucose uptake in L6 myotubes and 3T3L1
adipocytes at 24h
In an endeavor to identify a small molecule that could stimulate
glucose uptake like insulin, a cell based assay using L6 myoblast
and 3T3L1 preadipocytes was performed. These cells can be in-
duced to differentiate into myotubes and adipocyte phenotype,
as described previously thus serving as efﬁcient models to measure
glucose disposal [20]. The differentiated cells were treated with
AEG isolated from Cassia ﬁstula and incubated for 24 h. After the
incubation period the cells were assessed for insulin stimulated
2-deoxy-D-[1-3H] glucose uptake.
AEG (Fig. 1) isolated from Cassia ﬁstula methanolic extract
(CFME), enhanced glucose uptake in L6 myotubes and 3T3L1
Fig. 3. Inﬂuence of AEG on the cytotoxicity in L6 myotubes. Cytotoxic effect of AEG
measured on L6 myotubes as indicated doses of AEG at 24 h. Cytotoxicity was
expressed as % LDH release. Data represent the means ± S.E.M. of triplicates of three
independent experiments. *P < 0.05 as compared with untreated control group.
S. Anand et al. / FEBS Letters 584 (2010) 3170–3178 3173adipocytes in a concentration dependent manner and the optimum
dose exhibiting maximum activity was found to be 100 pg/ml
which was used for further studies (Fig. 2A and B). Additionally,
AEG was found to be non-toxic (less than 20% toxicity) even at high
concentration (10 lg/ml) (Fig. 3).
3.2. Effect of AEG on the inhibition of adipocyte differentiation
Two-day post conﬂuent, 3T3L1 preadipocytes were induced for
differentiation in the presence of logarithmic doses of AEG ranging
from 1 pg/ml to 1 lg/ml. Intracellular lipid content by AdipoRed
staining was performed to measure the degree of adipocyte differ-
entiation. When AEG was added to the preadipocytes in the
presence of differentiation medium only basal level lipid accumu-
lation was observed (Fig. 4A). Cytotoxicity assay by LDH release
measurement revealed that the AEG treated preadipocytes were
90% viable for the whole duration of the assay period. The differ-
ences in lipid accumulation of AEG treated adipocytes were photo-
micrographed at 10x magniﬁcation (Fig. 4B). However, AEG did not
alter the PPARc phosphorylation (Fig. 4C). The expression levels of
these proteins were subsequently semi-quantiﬁed by densitomet-
ric analysis (Fig. 4D).
3.3. Effect of AEG on IRTK and PI3K inhibition
To investigate whether AEG stimulated glucose uptake is med-
iated through tyrosine kinase dependent pathway, glucose uptakeFig. 2. Dose response analysis of AEG on 2-deoxy-D-3[H] glucose uptake on L6 myotubes
of AEG for 24 h in the presence and absence of insulin as mentioned in Section 2. After e
for 20 min and the uptake was measured. The results were expressed as % glucose upta
DMSO (solvent control) and cells and DMSO (solvent control) without insulin. The optim
data were expressed as means ± S.E.M. of three independent experiments. *P < 0.0001 aassay was performed with genistein (a tyrosine kinase inhibitor)
for 30 min, followed by treatment with insulin (100 nM) or AEG
for 24 h (Fig. 5). Genistein inhibited both insulin and AEG stimu-
lated glucose uptake. Hence the result suggested that AEG mimics
insulin, by acting via the tyrosine kinase dependent pathway. The
activation of PI3K is necessary for insulin stimulated glucose trans-
port [21]. To investigate whether AEG stimulated glucose uptake is
mediated through PI3K activation, we examined the effects ofand 3T3L1 adipocytes. (A and B) The cells were treated with different concentrations
xperimental incubation, 2-deoxy-D-3[H] glucose (0.5 lCi/ml) was added to the cells
ke with their respective controls which are cells treated with insulin (10 nM) and
um concentration of AEG was found to be 100 pg/ml for both L6 and 3T3L1. All the
s compared with respective control group.
Fig. 4. (A–D) Effect of AEG on lipid accumulation in 3T3L1 adipocyte after differentiation induction. (A) Two-day postconﬂuent 3T3-L1 cells were differentiated according to
the protocol followed by treatment with described doses of AEG or vehicle for 2 days. Eight days after induction of differentiation, cells were assayed for total triglyceride
content using Adipored reagent. Preadipocytes were separately maintained as per the protocol indicated. Data shown reﬂect the means ± S.E.M. of triplicates of two
determinations. *P < 0.0001 as compared with preadipocytes group. Photomicrographs were documented to evaluate the morphological changes of adipocytes at
magniﬁcation 100. (B) (a) Pre adipocyte (b) differentiation induced (c) differentiation induced + AEG. (C) Western blot analysis of PPARc using whole cell lysate of AEG
treated with L6 myotubes at different time points from 12, 24 and 36 h. (D) The protein was subsequently quantiﬁed by densitometry analysis. *P < 0.05 as compared with
untreated control group.
Fig. 5. Glucose transport behavior of AEG in the presence of inhibitors. L6 myotubes were pre-treated with AEG in addition of 100 nMWortmannin (WT) – PI3K inhibitor and
50 lM Genistein (GS) IRTK inhibitor at the concentration indicated and subjected to glucose uptake assay. Inhibitors suppressed the glucose uptake of AEG, which showed
uptake similar to that of positive control insulin. Rosiglitazone served as negative control and did not alter the glucose uptake in the presence of inhibitor. The results were
expressed as % change in glucose uptake with respect to the control. Data represent the means ± S.E.M. of triplicates of two independent experiments. *P < 0.05 as compared
with untreated control group.
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cose uptake. Interestingly, AEG stimulated glucose uptake in L6
myotubes declined (74% inhibition) on treatment with 100 nM
wortmannin (Fig. 5). These results suggest that the signal transduc-
tion leading to glucose uptake by AEG is primarily mediated via
PI3K pathway.
3.4. Effect of AEG on PTP1B inhibition
PTP1B has been implicated as the negative regulator of the insu-
lin signaling pathway. It dephosphorylates the speciﬁc phospho-
tyrosine residues on the insulin receptor thereby reducing theinsulin receptor tyrosine kinase (IRTK) activity. Hence inhibition
of this enzyme (PTP1B) would be validated as a therapeutic target
in the treatment of NIDDM as well as obesity. AEG was examined
for its effect on PTP1B inhibition at its optimum concentration. It
was found that AEG exhibited only a moderate PTP1B inhibition le-
vel as compared to the positive control SOV (sodium ortho vana-
date) (Fig. 6).
3.5. Effect of AEG on insulin signaling and GLUT4 translocation
Immunoprecipitation and immunoblot analysis revealed that
AEG (100 pg/ml) treatment on L6 myotubes for 24 h signiﬁcantly
Fig. 6. Effect of AEG on inhibition of PTP1B enzyme. AEG exhibited moderate
inhibition of PTP1B enzyme as compared with positive control sodium ortho
vanadate which showed maximum inhibition of PTP1B enzyme. Data represent the
means ± S.E.M. of triplicates of two independent experiments. *P < 0.0001 as
compared with untreated control.
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ers such as IRb, IRS1 and PI3K when compared to untreated cells
(Fig. 7A). The expression levels of these proteins were quantiﬁed
semi-quantitatively by densitometry analysis (Fig. 7B). The trans-
location pattern in response to AEG on L6 myotubes at 24 h was
analyzed (Fig. 8B). The AEG was able to translocate GLUT4 from
light microsomes to plasma membrane (PM). Insulin and RSG were
used as the positive controls. The majority of the GLUT4 transloca-
ting to PM upon AEG treatment similar to the positive controls wasFig. 7. (A) Western blot analysis of insulin signaling markers IRb, IRS1, PI3K, using
whole cell lysate of AEG treated with L6 myotubes at different time points from 12,
24 and 36 h. (B) The signaling intensities for semi-quantitative analysis of IRb, IRS1,
and PI3K protein expression were quantiﬁed by densitometry. Bars represent the
means ± S.E.M., n = 3 and a representative blot is depicted here. *P < 0.05 as
compared with untreated control group.observed (Fig. 8B and C). To determine the other downstream pro-
tein kinase in insulin signaling, the role of PKB phosphorylation
was examined (Fig. 9A). A signiﬁcant inhibition of GSK3b through
enhanced phosphorylation was observed in L6 myotubes treated
with AEG for 24 h. The results were quantiﬁed by densitometric
analysis (Fig. 9B).
3.6. Effect of AEG on glycogen synthesis activation
Insulin stimulated transformation of glucose into glycogen was
signiﬁcantly high upon AEG treatment (121% at 100 pg/ml)
(Fig. 10). Similarly, AEG showed a considerable increase in glyco-
gen synthesis even in the absence of insulin stimulation. Effect of
AEG in glycogen synthesis was compared with positive control
insulin (100 nM).
4. Discussion
The current study reveals the glucose transporting efﬁcacy of
Aloe emodin glycosides and demonstrates the molecular mecha-
nism involved in mediating insulin signaling pathway through an
in vitro model. Pathogenesis of NIDDM involves a combination of
genetic and environmental factors, which cause insulin resistance
in target tissues [22]. Skeletal muscle is the primary site for insulin
stimulated glucose uptake and a large part of the glucose incorpo-
rated into muscle cells is deposited as glycogen in response to
insulin. Thus, glucose uptake and glycogen synthesis in skeletal
muscle play a pivotal role in blood glucose homeostasis. The
importance of IRTK and PI3K has been well established in the insu-
lin downstream signal transduction particularly by the activation
of insulin receptor through autophosphorylation followed by
sequential events of PI3K activation [23] ultimately resulting in
GLUT4 translocation [24]. The impaired glucose uptake linked with
defect in GLUT4 translocation and impaired insulin signaling cas-Fig. 8. (A) Western blot analysis of total GLUT4 of AEG at different time points from
12, 24 and 36 h on L6 myotubes. (B and C) Effect of AEG on translocation of GLUT4
at 24 h on L6 myotubes semi-quantitatively. Insulin (100 nM) and rosiglitazone
(50 lM) were used as positive controls. Bars represent the means ± S.E.M., n = 3 and
a representative blot is depicted here. **P < 0.05 as compared with untreated
control group.
Fig. 9. Effect of AEG on (A) protein expression of PKB, GSK3b treated with L6
myotubes at 12, 24 and 36 h. (B) The protein expressions were normalized using
representative non-phosphorylated proteins. Bars represent the means ± S.E.M. of
PKB and GSK-3b. *P < 0.05 as compared with untreated control group.
Fig. 10. Dose response analysis of glycogen synthesis in AEG treated cells at 24 h in
the presence and absence of insulin. The results were expressed as% of glucose
incorporated into glycogen with their respective controls which are cells treated
with insulin (10 nM) and DMSO (solvent control) and cells and DMSO (solvent
control) without insulin. Data represent the mean ± S.E.M. of triplicates of two
independent experiments. *P < 0.05 as compared with respective control group.
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serine/threonine kinase Akt, also known as protein kinase B
(PKB) could play a role in the activation of glucose uptake and gly-
cogen synthesis in L6 myotubes [26], in addition to being a central
intermediate for many of the insulin and growth factor responses
downstream of PI3K. Akt has been identiﬁed as one of the insulin
responsive kinases that phosphorylates glycogen synthase ki-
nase-3 (GSK-3) [27]. Subsequent studies have demonstrated that
Akt has a role in promoting GLUT4 translocation in adipocytes
[28], glucose transport and glycogen synthesis in L6 myotubes
[29].
An insulin mimetic molecule from a fungus activating IRTK and
PI3K [30] has been isolated. Previous studies have postulated that
triterpenoids act as insulin-mimicker by activating IRb, IRS1 and
GLUT4 translocation [31,32] which coincides well with the resultsobtained with AEG treated cells. 2-deoxy-D-3[H] glucose uptake
assay was performed by AEG in a dose dependent manner in both
L6 myotubes and 3T3L1 adipocytes. AEG exhibited signiﬁcant in-
crease in glucose uptake by L6 myotubes and 3T3L1 adipocytes
at 120% and 140% respectively. The percentage uptake was calcu-
lated on par with the positive control RSG which showed an uptake
of 165%. Lactate dehydrogenase (LDH) release in L6 myotubes on
treatment with AEG at 24 h incubation shows that AEG is non-toxic
even at higher concentrations.
Insulin exerts its biological effect upon binding with insulin
receptor (IR) thereby stimulating the downstream signaling events
that lead to enhanced glucose uptake. In skeletal muscle, it poten-
tiates the glucose transport through PI3K mediated and non-PI3K
mediated pathways. Alterations in the level of IR or defects in its
signal transduction pathway have been found in diabetic patients
associated with decreased levels of IRb, IRS-1 and PI3K [33]. To re-
veal the molecular mechanism of AEG, in augmenting glucose
transport, and its effect on phosphorylated level of IRb, IRS1 and
PI3K western blot analysis was performed. Pessin et al. have
emphasized the major role of PI3K in insulin signaling pathway
and in regulating insulin-mediated glucose transport [34]. To
examine whether AEG stimulates glucose transport in a PI3K
dependent manner, western blot analysis and phospho-detect
p85PI3K were employed. The expression of PI3K is substantiated
by the enhanced expression of the catalytic subunit of PI3K on
treatment with AEG. A time dependent analysis showed an in-
crease in the phosphorylation of IRb, IRS1, PI3K clearly indicating
that AEG acts through a PI3K dependent pathway. RSG was used
as the negative control since it upregulates glucose uptake in a
PI3K independent manner. The above ﬁnding conﬁrms that the in-
creased uptake of glucose exhibited by AEG is through the activa-
tion of GLUT4. This observation also correlates with the inhibitor
studies performed using genistein (IRTK inhibitor) and wortman-
nin (PI3K inhibitor). In conclusion, it is observed that the insulin
like activity of AEG in upregulating glucose transportation is IRTK
and PI3K mediated.
GLUT4 is the predominant glucose transporter among various
isotypes of glucose transporters in insulin sensitive tissues like
skeletal muscle and adipocytes, which transports glucose from
blood into tissue. Decrease in the translocation of GLUT4 to the
PM has been a major cause of insulin resistance. It is therefore
essential to activate GLUT4 in skeletal muscle to alleviate insulin
resistance and to maintain blood glucose homeostasis. Metformin
and troglitazone enhance insulin stimulated glucose uptake by
increasing the cell surface GLUT4 content [35]. Semi-quantitative
analysis of GLUT4 translocation was performed by sub-cellular
fractionation of cell lysates in order to separate the LM and the
PM. For assessing whether the increased glucose uptake stimulated
by AEG was due to the translocation of GLUT4, the amounts of
GLUT4 present in LM and PM was measured after the treatment
of AEG on L6 myotubes at 24 h. AEG was able to translocate major-
ity of the GLUT4 from light microsomes to PM. Insulin and RSG
served as the positive control and were able to translocate GLUT4
to PM at 15 min and 24 h respectively. The process of translocation
of GLUT4 to PM was quantiﬁed using densitometry scanning.
Further, probing the role of insulin in glycogen synthesis, Akt/
PKB is a downstream event of PI3K and plays an important role
in insulin-mediated glucose transport as well as glycogen synthesis
[36]. Activated PKB increases glycogen synthesis through an inhibi-
tion of GSK3b [37,38]. Constitutively active GSK3b is the major
contributor of insulin resistance and it serves as a gatekeeper by
negatively regulating the insulin receptor signal in the absence of
stimulus. So identifying a potent molecule that activates glucose
storage through an activation of PKB and inhibition of GSK3b
would be an interesting ﬁnding. Based on this, AEG was examined
for its role in PKB and GSK3b phosphorylation. AEG showed signif-
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prominent role in modulating glycogen synthesis through an acti-
vation of PKB and inactivation of GSK3b.
In addition, the effect of AEG on adipogenesis was assessed in
3T3L1 adipocytes. Adipogenesis, the process of preadipocyte differ-
entiation into adipocytes is controlled by various positive and neg-
ative regulators such as hormones, adipogenic genes, adipokines
and growth factors [39]. PPARc, CCAAT/enhancer binding protein
and sterol regulatory element binding protein families are well-
documented primary adipogenic transcription factors involved in
adipocyte differentiation and among them PPARc is the most
extensively studied and clinically validated adipogenic gene for
therapeutic utility in type 2 diabetes [40]. Upregulation of PPARc
gene by thiazolidinediones in skeletal muscle has been reported
to improve insulin sensitivity and glucose uptake [12]. Although
relatively beneﬁcial for their anti-diabetic action, thiazolidinedi-
ones have been reported to cause abnormalities in lipid metabo-
lism and cardiac side-effects [41]. In the present analysis, 3T3L1
adipocytes incubated with AEG clearly revealed a signiﬁcant de-
crease in lipid droplets formations and did not alter the PPARc pro-
tein expression. AEG also inhibits adipocyte differentiation in
3T3L1 adipocytes that correlates with our observation of PPARc
phosphorylation. Hence it can be concluded that AEG exhibits glu-
cose-lowering efﬁcacy without inducing adipogenesis.
Since the observed effect of AEG on insulin signaling markers,
glucose uptake, adipogenesis and glycogen synthesis are distinc-
tive activity proﬁle for both PTP1B inhibitors [42] and AMPK acti-
vators [43], AEG was assessed for PTP1B inhibition and compared
with known PTP1B inhibitor (SOV). The tyrosine phosphorylation
of the insulin receptor and its substrates is countered by dephos-
phorylation of the protein phosphatases like protein phosphatase
1B (PTP1B). In case of insulin resistance, the dephosphorylation
of these phosphatases exerts the phosphorylation of insulin recep-
tor and its substrates [44,45]. A decrease in adipogenesis with a
down regulation of all adipogenic genes in animals ablated with
PTP1B was postulated to play a pivotal role in the development
of obesity [46]. The moderate effect of AEG on PTP1B inhibition
eliminates the possibility of AEG as a potent PTP1B inhibitor. In
conclusion, AEG exhibits insulin mimetic activity by activating
IRb, IRS1, p85 subunit of PI3K, PKB and GLUT4 translocation and
inhibiting GSK3b phosphorylation, thus upregulating glucose up-
take and storage respectively in a PI3K dependent pathway. Based
on these inferences AEG could be validated as an anti-diabetic mol-
ecule deﬁcient of adipogenic activity providing an opportunity to
develop a novel class of drug that is more effective in the treatment
of insulin resistance.
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